Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
On April 25, 2023, Danaher Corporation (NYSE: DHR) disclosed its Q1 2023 financial results. The company reported net earnings of $1.4 billion or $1.94 per diluted share, alongside non-GAAP adjusted earnings of $2.36 per share. Total revenues fell 7.0% year-over-year to $7.2 billion, attributed to reduced COVID-19 revenue, while core revenue decreased by 4.0%. However, the base business core revenue grew 6.0%. The operating cash flow for the quarter stood at $1.9 billion, with free cash flow at $1.7 billion. For Q2 and the full year, non-GAAP base business core revenue growth is projected to be in the mid-single digits. CEO Rainer M. Blair noted a strong start despite challenges, highlighting a robust business outlook.
Danaher Corporation (NYSE: DHR) announced that its 5.00% Series B Mandatory Convertible Preferred Stock will convert automatically into common stock on April 17, 2023. Shareholders will receive 5.0175 shares of common stock for each share of Preferred Stock. Additionally, a final quarterly cash dividend of $12.50 per share will be distributed to Preferred Stock holders of record as of March 31, 2023, paid on the conversion date of April 17, 2023, due to the prior dividend date falling on a weekend.
This strategic move simplifies capital structure while rewarding investors with equity and dividend payments.
Danaher Corporation (NYSE: DHR) has scheduled its first quarter 2023 earnings conference call for April 25, 2023, at 8:00 a.m. ET. The call will focus on the company's financial performance and future expectations, lasting approximately one hour.
Listeners can access the call via telephone or through a webcast on Danaher's website. The earnings press release and presentation materials will also be available on the site starting at 6:00 a.m. ET on the day of the call.
Danaher Corporation (NYSE: DHR) has announced a strategic partnership with the University of Pennsylvania to enhance cell therapy innovation. This multi-year collaboration aims to develop technologies that improve clinical outcomes and address manufacturing bottlenecks associated with engineered cell products. Currently, there are six FDA-approved CAR T cell therapies and over 560 programs in clinical trials, highlighting significant potential in the biopharma industry. Both parties believe that advancing manufacturing innovation will help deliver next-generation therapies to patients more efficiently.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.27 per share for its common stock, set for payment on April 28, 2023, to stockholders of record by March 31, 2023. Additionally, a quarterly cash dividend of $12.50 per share for the 5.00% Series B Mandatory Convertible Preferred Stock will be paid on April 17, 2023, also to holders of record by March 31, 2023. Danaher focuses on solving complex challenges through its global science and technology initiatives, with a diverse workforce of about 81,000 employees.
Danaher Corporation (NYSE: DHR) announced the creation of a new public entity, Veralto Corporation, expected to launch in Q4 2023. Veralto will encompass Danaher’s Environmental and Applied Solutions (EAS) segment, which generated approximately $4.8 billion in revenue in 2022 and employs about 16,000 individuals. This standalone company will be led by Jennifer L. Honeycutt, Danaher's Executive VP. Veralto aims to list under the symbol VLTO on the New York Stock Exchange and will focus on improving global access to vital resources, including safe food and water. The name reflects the company's commitment to excellence.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
